Nuclear factor-?B signalling and transcriptional regulation in skeletal muscle atrophy

被引:67
作者
Jackman, Robert W. [1 ]
Cornwell, Evangeline W. [1 ]
Wu, Chia-Ling [1 ]
Kandarian, Susan C. [1 ]
机构
[1] Boston Univ, Dept Hlth Sci, Boston, MA 02215 USA
关键词
NF-KAPPA-B; CANCER CACHEXIA; GENE-PRODUCTS; ACTIVATION; INFLAMMATION; PATHWAYS; CONTRIBUTES; HOMODIMERS; EXPRESSION; INDUCTION;
D O I
10.1113/expphysiol.2011.063321
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The nuclear factor-kappa B (NF-kappa B) signalling pathway is a necessary component of adult skeletal muscle atrophy resulting from systemic illnesses or disuse. Studies showing a role for the NF-kappa B pathway in muscle disuse include unloading, denervation and immobilization, and studies showing a role for NF-kappa B in systemic illnesses include cancer, chronic heart failure and acute septic lung injury. Muscle atrophy due to most of these triggers is associated with activation of NF-kappa B transcriptional activity. With the exception of muscle unloading, however, there is a paucity of data on the NF-kappa B transcription factors that regulate muscle atrophy, and little is known about which genes are targeted by NF-kappa B transcription factors during atrophy. Interestingly, in some cases it appears that the amelioration of muscle atrophy by genetic inhibition of NF-kappa B signalling proteins is due to effects that are independent of the downstream NF-kappa B transcription factors. These questions are prime areas for investigation if we are to understand a key component of muscle wasting in adult skeletal muscle.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 36 条
[1]   Dystrophin glycoprotein complex dysfunction: A regulatory link between muscular dystrophy and cancer cachexia [J].
Acharyya, S ;
Butchbach, MER ;
Sahenk, Z ;
Wang, HT ;
Saji, M ;
Carathers, M ;
Ringel, MD ;
Skipworth, RJE ;
Fearon, KCH ;
Hollingsworth, MA ;
Muscarella, P ;
Burghes, AHM ;
Rafael-Fortney, JA ;
Guttridge, DC .
CANCER CELL, 2005, 8 (05) :421-432
[2]   Cancer cachexia is regulated by selective targeting of skeletal muscle gene products [J].
Acharyya, S ;
Ladner, KJ ;
Nelsen, LL ;
Damrauer, J ;
Reiser, PJ ;
Swoap, S ;
Guttridge, DC .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (03) :370-378
[3]   Nuclear factor-kappa B activation in skeletal muscle of patients with chronic heart failure:: correlation with the expression of inducible nitric oxide synthase [J].
Adams, V ;
Späte, U ;
Kränkel, N ;
Schulze, PC ;
Linke, A ;
Schuler, G ;
Hambrecht, R .
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2003, 10 (04) :273-277
[4]   NF-κB Signaling: A Tale of Two Pathways in Skeletal Myogenesis [J].
Bakkar, Nadine ;
Guttridge, Denis C. .
PHYSIOLOGICAL REVIEWS, 2010, 90 (02) :495-511
[5]   JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia [J].
Bonetto, Andrea ;
Aydogdu, Tufan ;
Jin, Xiaoling ;
Zhang, Zongxiu ;
Zhan, Rui ;
Puzis, Leopold ;
Koniaris, Leonidas G. ;
Zimmers, Teresa A. .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2012, 303 (03) :E410-E421
[6]   THE ONCOPROTEIN BCL-3 DIRECTLY TRANSACTIVATES THROUGH KAPPA-B MOTIFS VIA ASSOCIATION WITH DNA-BINDING P50B HOMODIMERS [J].
BOURS, V ;
FRANZOSO, G ;
AZARENKO, V ;
PARK, S ;
KANNO, T ;
BROWN, K ;
SIEBENLIST, U .
CELL, 1993, 72 (05) :729-739
[7]   NF-κB-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-κB1 residence [J].
Brasier, AR ;
Lu, MP ;
Hai, T ;
Lu, Y ;
Boldogh, I .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (34) :32080-32093
[8]   IKKβ/NF-κB activation causes severe muscle wasting in mice [J].
Cai, DS ;
Frantz, JD ;
Tawa, NE ;
Melendez, PA ;
Oh, BC ;
Lidov, HGW ;
Hasselgren, PO ;
Frontera, WR ;
Lee, J ;
Glass, DJ ;
Shoelson, SE .
CELL, 2004, 119 (02) :285-298
[9]   The NF-κB-independent functions of IKK subunits in immunity and cancer [J].
Chariot, Alain .
TRENDS IN CELL BIOLOGY, 2009, 19 (08) :404-413
[10]   IKK-dependent, NF-κB-independent control of autophagic gene expression [J].
Comb, W. C. ;
Cogswell, P. ;
Sitcheran, R. ;
Baldwin, A. S. .
ONCOGENE, 2011, 30 (14) :1727-1732